Bamboo extract lowers stress genes in diabetic rats, docking study finds

A new study in Molecular Biology Reports reports that an aqueous extract of Bambusa vulgaris, a tropical bamboo species long used in traditional medicine, lowered the expression of genes linked to endoplasmic reticulum stress in rats with chemically induced stress, while several compounds isolated from the plant bound strongly to a key stress-signaling protein in computer simulations. The work, led by Yetunde Victoria Aladenika and colleagues, combines animal experiments with molecular docking to explore how the plant might act on a cellular pathway implicated in insulin resistance and diabetes mellitus.

The researchers induced endoplasmic reticulum stress in thirty experimental rats by injecting 60 mg/kg of streptozotocin dissolved in citrate buffer. The animals were divided into six groups of five: a control group, an untreated endoplasmic reticulum stress group, a group receiving the antidiabetic drug metformin at 100 mg/kg, and three groups given oral doses of the bamboo extract at 50, 100, or 200 mg/kg. Fasting blood glucose was tracked with a glucometer, and gene expression was measured by RT-PCR after 21 days of treatment.

Within 72 hours of streptozotocin induction, the mRNA levels of four endoplasmic reticulum stress markers — GRP78, CHOP, ATF4, and PERK — were markedly upregulated compared with the control animals, with statistical significance set at p < 0.05. Treatment with the bamboo extract at 50 and 100 mg/kg significantly downregulated the expression of these genes relative to the untreated stressed rats. The authors report that the extract also promoted normoglycemia, although the abstract does not highlight the 200 mg/kg dose as significant for gene downregulation.

On the computational side, the team used Schrödinger software to dock Bambusa vulgaris phytocompounds against PERK, the protein kinase that anchors one arm of the unfolded protein response. Two compounds stood out in standard molecular docking: luteolin, with a docking score of -10.764 kcal/mol, and chlorogenic acid, at -10.725 kcal/mol. When the researchers refined the poses with induced-fit docking, which allows the protein binding site to flex around the ligand, both compounds retained strong scores, and their calculated free binding energies were -42.2 kcal/mol and -39.33 kcal/mol, respectively. Both molecules also complied with Lipinski’s rules of drug-likeness, structural criteria used to flag compounds with properties compatible with an oral drug.

The strongest computed binding energy in the study belonged to a third compound. Isovitexin recorded a free binding energy of -50.91 kcal/mol, the lowest value reported in the analysis, suggesting the tightest computed interaction with PERK among the phytocompounds screened. The authors also performed ADMET profiling, which estimates absorption, distribution, metabolism, excretion, and toxicity properties, for the bamboo compounds alongside the docking work.

The findings place the study within a body of research connecting endoplasmic reticulum stress to metabolic disease. By showing that streptozotocin reliably raises GRP78, CHOP, ATF4, and PERK expression in this rat model, and that the plant extract appears to blunt that rise, the authors offer a mechanistic hypothesis for the antidiabetic reputation of Bambusa vulgaris in traditional medicine.

The authors conclude that the extract and its constituent compounds downregulate genes associated with endoplasmic reticulum stress and promote normoglycemia. They frame the docking results as supporting evidence that specific phytocompounds may interact directly with PERK, positioning luteolin, chlorogenic acid, and isovitexin as candidates for further investigation.

Several caveats temper the interpretation. All gene-expression and glucose findings come from a small animal experiment with five rats per group over three weeks, and the computational results are model-based estimates of binding rather than measured biological activity; a favorable docking score does not establish that a compound inhibits PERK in living tissue. The study does not demonstrate efficacy in humans, and the abstract does not report detailed dose-response data or long-term safety outcomes. Translating these observations into therapeutic claims would require controlled studies beyond this model. Still, the combination of in vivo gene-expression data with computational binding analysis provides a coherent, testable picture of how a traditional medicinal bamboo might interact with one of the central stress pathways in diabetes, and it identifies specific molecular candidates that future laboratory work can examine directly.

Subject of Research: Effects of Bambusa vulgaris phytocompounds on endoplasmic reticulum stress gene expression and PERK docking in streptozotocin-treated rats

Article Title: Gene expression, MMGBSA, molecular and induced-fit docking of Bambusa vulgaris phytocompounds in endoplasmic reticulum stress induced by streptozotocin

Article References: Aladenika, Y. V., Akinjiyan, M. O., Ojo, F. M., Tanimowo, O. B., Elekofehinti, O. O., & Adanlawo, I. G. (2026). Gene expression, MMGBSA, molecular and induced-fit docking of Bambusa vulgaris phytocompounds in endoplasmic reticulum stress induced by streptozotocin. Molecular Biology Reports, 53(1), Article 1797. https://doi.org/10.1007/s11033-026-13026-9

Image Credits: AI Generated

DOI: 10.1007/s11033-026-13026-9

Keywords: Bambusa vulgaris, endoplasmic reticulum stress, streptozotocin, PERK, GRP78, CHOP, ATF4, molecular docking, MMGBSA, luteolin, chlorogenic acid, isovitexin